150 related articles for article (PubMed ID: 31245054)
1. Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a
McInnes IB; Ferraccioli G; D'Agostino MA; Le Bars M; Banerjee S; Ahmad HA; Elbez Y; Mease PJ
RMD Open; 2019; 5(1):e000934. PubMed ID: 31245054
[TBL] [Abstract][Full Text] [Related]
2. Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis.
Mease PJ; McInnes IB; Strand V; FitzGerald O; Ahmad HA; Elbez Y; Banerjee S
Rheumatol Int; 2020 Jul; 40(7):1021-1028. PubMed ID: 32356115
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Mease PJ; Gottlieb AB; van der Heijde D; FitzGerald O; Johnsen A; Nys M; Banerjee S; Gladman DD
Ann Rheum Dis; 2017 Sep; 76(9):1550-1558. PubMed ID: 28473423
[TBL] [Abstract][Full Text] [Related]
4. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial.
Strand V; Alemao E; Lehman T; Johnsen A; Banerjee S; Ahmad HA; Mease PJ
Arthritis Res Ther; 2018 Dec; 20(1):269. PubMed ID: 30522501
[TBL] [Abstract][Full Text] [Related]
5. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
[TBL] [Abstract][Full Text] [Related]
6. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
10. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
[TBL] [Abstract][Full Text] [Related]
11. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
[TBL] [Abstract][Full Text] [Related]
12. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
[TBL] [Abstract][Full Text] [Related]
14. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
[TBL] [Abstract][Full Text] [Related]
15. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Mease P; Genovese MC; Gladstein G; Kivitz AJ; Ritchlin C; Tak PP; Wollenhaupt J; Bahary O; Becker JC; Kelly S; Sigal L; Teng J; Gladman D
Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
[TBL] [Abstract][Full Text] [Related]
16. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A
Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
[TBL] [Abstract][Full Text] [Related]
18. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
[TBL] [Abstract][Full Text] [Related]
19. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
20. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]